Dehydrofelodipine is a synthetic compound that acts as a calcium channel blocker. It is a derivative of felodipine, a widely used antihypertensive drug. Dehydrofelodipine is structurally similar to felodipine, but it has a double bond in the dihydropyridine ring, which enhances its lipophilicity and increases its bioavailability. The compound exhibits high selectivity for L-type calcium channels, which are found in the heart, vascular smooth muscle, and other tissues. Dehydrofelodipine inhibits the influx of calcium ions into cells, leading to relaxation of vascular smooth muscle and a decrease in blood pressure. It has been studied for its potential therapeutic applications in the treatment of hypertension, angina pectoris, and other cardiovascular conditions. The compound's synthesis involves a multi-step process starting with the preparation of a dihydropyridine derivative. It has been shown to be effective in reducing blood pressure in animal models and in human clinical trials. Its research importance lies in its potential as a more potent and effective calcium channel blocker for the management of cardiovascular diseases.'
dehydrofelodipine: the primary pyridine metabolite of felodipine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 62970 |
| CHEBI ID | 180623 |
| SCHEMBL ID | 6949718 |
| MeSH ID | M0218097 |
| Synonym |
|---|
| CHEBI:180623 |
| 3-o-ethyl 5-o-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate |
| felodipine m (dehydro) |
| dehydrofelodipine |
| 96382-71-7 |
| FT-0665615 |
| 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester |
| h152/37 |
| h 152/37 |
| 1l4a1ep86i , |
| unii-1l4a1ep86i |
| dehydro felodipine |
| 4-(2,3-dichlorophenyl)-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester |
| REQRUBNOOIAHMG-UHFFFAOYSA-N |
| SCHEMBL6949718 |
| Q-201088 |
| ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate |
| Q-201108 |
| 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-2,6-dimethyl-, 3-ethyl 5-methyl ester |
| felodipine impurity a [ep impurity] |
| h-152/37 |
| 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate |
| DTXSID90242215 |
| AKOS030255825 |
| felodipine ep impurity a;dehydro felodipine |
| BCP33557 |
| Q27252561 |
| A900163 |
| AS-78573 |
| CS-0366077 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " With increasing age the plasma concentrations and the terminal half-life of felodipine increased, whereas the plasma clearance and the ratio of the AUC of the primary pyridine metabolite to that of unchanged drug decreased." | ( Felodipine pharmacokinetics and plasma concentration vs effect relationships. Blychert, E, 1992) | 0.28 |
| " Grapefruit juice drunk simultaneously with and 1, 4, 10 or 24 hours before the drug administration resulted in a 32-99% increase in mean Cmax values of felodipine, relative to concomitant water and felodipine intake." | ( Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1995) | 0.29 |
| "Intake of grapefruit juice did not significantly alter the intravenous pharmacokinetics of felodipine compared to control treatment, whereas after oral drug administration it did lead to an increase in the mean AUC and Cmax by 72% and 173%, respectively, and the mean absolute bioavailability was increased by 112%." | ( Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1997) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The time to maximum plasma felodipine concentration, the bioavailability and the volume of distribution were not consistently influenced by age." | ( Felodipine pharmacokinetics and plasma concentration vs effect relationships. Blychert, E, 1992) | 0.28 |
| " The interaction could not be predicted from baseline pharmacokinetics with water and did not result in more consistent bioavailability among individuals." | ( Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin. Arnold, JM; Bailey, DG; Munoz, C; Spence, JD, 1993) | 0.29 |
| "Intake of grapefruit juice did not significantly alter the intravenous pharmacokinetics of felodipine compared to control treatment, whereas after oral drug administration it did lead to an increase in the mean AUC and Cmax by 72% and 173%, respectively, and the mean absolute bioavailability was increased by 112%." | ( Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1997) | 0.3 |
| "Grapefruit juice can increase the oral bioavailability of a broad range of medications." | ( Grapefruit juice--felodipine interaction in the elderly. Bailey, DG; Carruthers, SG; Dresser, GK, 2000) | 0.31 |
| "Our study was designed to determine the effect of peppermint oil and ascorbyl palmitate on cytochrome P4503A4 (CYP3A4) activity in vitro and oral bioavailability of felodipine in humans." | ( Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Bailey, DG; Dresser, GK; Wacher, V; Wong, HT; Wong, S, 2002) | 0.31 |
| " Grapefruit juice increased the oral bioavailability of felodipine by inhibition of CYP3A4-mediated presystemic drug metabolism." | ( Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Bailey, DG; Dresser, GK; Wacher, V; Wong, HT; Wong, S, 2002) | 0.31 |
| Class | Description |
|---|---|
| phenylpyridine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (100.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 0 (0.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||